MedTrace Logo

PD-L1 PET Imaging in Patients With the Immunotherapy for Non-small Cell Lung Cancer

NCT05533086 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 20

Last updated 2023-02-13

No results posted yet for this study

Summary

Clinical trials have shown efficacy of PD1/PD-L1 checkpoint inhibitors in multiple solid tumors, including NSCLC. Whole body information with regard to target presence, drug kinetics and dynamics, as well as binding of PD-L1 targeting agents to the immune system cells is lacking.Molecular imaging of PD-L1 could lead to new insights on heterogeneity of PD-L1 expression in metastatic lesions and be of help in the prediction of response to PD1/PD-L1 inhibitors in a noninvasive manner.

Conditions

  • NSCLC Stage IV
  • PD-L1 Gene Amplification

Sponsors & Collaborators

  • Xiaohua Zhu

    lead OTHER

Principal Investigators

  • ZHU XIAOHUA, DR · Tongji Hospital

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2022-08-16
Primary Completion
2024-08-31
Completion
2025-08-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05533086 on ClinicalTrials.gov